Neuralink received FDA approval to begin human trials and, in January 2024, implanted its device in its first human participant, who was subsequently able to control a computer cursor and play games using neural signals alone. Pre-clinical animal testing — which drew criticism — follows the standard regulatory pathway required before human trials. Whether it ultimately scales is an open question, but real, regulator-supervised results exist.